AIDS vaccine focus shifts after disappointments
WASHINGTON (Reuters) - A global AIDS vaccine conference this week will seek fresh strategies against the HIV virus, with experts weighing the value of basic laboratory research against large-scale human clinical trials after a string of disappointments.
<p><img src="http://feedads.googleadservices.com/~a/A4tn_ZEKvF7DvsBx4zRRK1dhp3I/i" border="0" ismap="true"></img> (http://feedads.googleadservices.com/~a/A4tn_ZEKvF7DvsBx4zRRK1dhp3I/a)</p><div class="feedflare">
<img src="http://feedproxy.google.com/~f/Reuters/domesticNews?d=41" border="0"></img> (http://feeds.reuters.com/~f/Reuters/domesticNews?a=e2FfkXlp) <img src="http://feedproxy.google.com/~f/Reuters/domesticNews?i=2aixoq0c" border="0"></img> (http://feeds.reuters.com/~f/Reuters/domesticNews?a=2aixoq0c) <img src="http://feedproxy.google.com/~f/Reuters/domesticNews?i=l1b6If2X" border="0"></img> (http://feeds.reuters.com/~f/Reuters/domesticNews?a=l1b6If2X)
</div><img src="http://feedproxy.google.com/~r/Reuters/domesticNews/~4/B17P1Z1Sr64" height="1" width="1"/>
http://feeds.reuters.com/~r/Reuters/domesticNews/~3/B17P1Z1Sr64/idUSTRE49B1T820081012